The Genomics in Cancer Care Market is being reshaped by artificial intelligence (AI), cloud platforms, and clinical decision support systems that make complex cancer genomics usable at scale. With the market projected to grow from about USD 53.66 billion in 2025 to nearly USD 220 billion by 2035, digital infrastructure is becoming just as important as sequencing instruments.

AI and machine learning are now central to interpreting genomic data. Algorithms help classify variants, predict pathogenicity, identify potential drug targets, and suggest clinical trial matches based on a tumor’s molecular profile. This reduces the burden on molecular tumor boards and enables smaller hospitals to access expertise that was once limited to major academic centers.

Cloud-based platforms are another key enabler. They allow genomic data to be stored securely, processed at scale, and shared across institutions and geographies. This supports multicenter research, real-world evidence generation, and harmonized care standards. Integration with electronic health records and oncology information systems ensures genomic results are available when and where clinicians need them.

FAQs
Q1. How does AI support cancer genomics?
By automating variant interpretation, suggesting targeted therapies, and helping match patients to clinical trials.

Q2. Why are cloud platforms important?
They provide scalable storage and processing power, enabling secure sharing and analysis of large genomic datasets.

Tags: AI in cancer genomics, cloud genomics, clinical decision support, precision oncology platforms, genomics in cancer care, digital health, oncology IT